Operating Expenses
Total Operating Expenses
Alnylam Pharmaceuticals Total Operating Expenses decreased by 6.9% to $898.54M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 56.0%, from $576.11M to $898.54M. Over 4 years (FY 2021 to FY 2025), Total Operating Expenses shows an upward trend with a 19.9% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Rising expenses without a corresponding rise in revenue can indicate operational bloat or aggressive expansion efforts.
Detailed definition
The sum of all costs required to run the business that are not directly tied to production, including R&D and SG&A. It r...
Peer comparison
Investors compare this to revenue to assess the 'operating leverage' of a business model.
Metric ID:
total_operating_expensesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $366.71M | $369.31M | $453.10M | $359.99M | $416.50M | $522.35M | $523.65M | $469.10M | $548.59M | $536.66M | $556.12M | $537.77M | $611.21M | $577.82M | $698.33M | $576.11M | $789.89M | $881.04M | $965.32M | $898.54M |
| QoQ Change | — | +0.7% | +22.7% | -20.5% | +15.7% | +25.4% | +0.2% | -10.4% | +16.9% | -2.2% | +3.6% | -3.3% | +13.7% | -5.5% | +20.9% | -17.5% | +37.1% | +11.5% | +9.6% | -6.9% |
| YoY Change | — | — | — | — | +13.6% | +41.4% | +15.6% | +30.3% | +31.7% | +2.7% | +6.2% | +14.6% | +11.4% | +7.7% | +25.6% | +7.1% | +29.2% | +52.5% | +38.2% | +56.0% |
Range$359.99M – $965.32M
CAGR+20.8%
Avg YoY Growth+24.0%
Median YoY Growth+20.6%
Total Operating Expenses at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's total operating expenses?
- Alnylam Pharmaceuticals (ALNY) reported total operating expenses of $898.54M in Q1 2026.
- How has Alnylam Pharmaceuticals's total operating expenses changed year-over-year?
- Alnylam Pharmaceuticals's total operating expenses increased by 56.0% year-over-year, from $576.11M to $898.54M.
- What is the long-term trend for Alnylam Pharmaceuticals's total operating expenses?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's total operating expenses has grown at a 19.9% compound annual growth rate (CAGR), from $1.55B to $3.21B.
- What does total operating expenses mean?
- The total cost of running the day-to-day business, excluding the direct cost of making products.